ATE503025T1 - Verfahren zur bestimmung der prognose eines adenokarzinoms - Google Patents

Verfahren zur bestimmung der prognose eines adenokarzinoms

Info

Publication number
ATE503025T1
ATE503025T1 AT07799622T AT07799622T ATE503025T1 AT E503025 T1 ATE503025 T1 AT E503025T1 AT 07799622 T AT07799622 T AT 07799622T AT 07799622 T AT07799622 T AT 07799622T AT E503025 T1 ATE503025 T1 AT E503025T1
Authority
AT
Austria
Prior art keywords
adenocarcinoma
prognosis
determining
organ
methods
Prior art date
Application number
AT07799622T
Other languages
English (en)
Inventor
Curtis Harris
Masahiro Seike
Xin Wang
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE503025T1 publication Critical patent/ATE503025T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
AT07799622T 2006-07-14 2007-07-16 Verfahren zur bestimmung der prognose eines adenokarzinoms ATE503025T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83093606P 2006-07-14 2006-07-14
US88510107P 2007-01-16 2007-01-16
PCT/US2007/073637 WO2008009028A2 (en) 2006-07-14 2007-07-16 Methods of determining the prognosis of an adenocarcinoma

Publications (1)

Publication Number Publication Date
ATE503025T1 true ATE503025T1 (de) 2011-04-15

Family

ID=38670673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07799622T ATE503025T1 (de) 2006-07-14 2007-07-16 Verfahren zur bestimmung der prognose eines adenokarzinoms

Country Status (5)

Country Link
US (1) US9464324B2 (de)
EP (1) EP2041313B1 (de)
AT (1) ATE503025T1 (de)
DE (1) DE602007013405D1 (de)
WO (1) WO2008009028A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110183859A1 (en) * 2008-09-25 2011-07-28 The United States Of America, As Represented By The Secretary, Inflammatory genes and microrna-21 as biomarkers for colon cancer prognosis
RU2455924C1 (ru) * 2011-03-30 2012-07-20 Учреждение Российской академии наук Институт физиологии природных адаптаций Уральского отделения Российской академии наук Способ прогнозирования метастазирования опухолевого процесса у больных раком желудка
CA2974175A1 (en) 2014-02-24 2015-08-27 Immunepharma S.R.L. Lung cancer's biomarkers and their methods and diagnostic kit

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985829A (en) * 1994-12-19 1999-11-16 The United States Of America As Represented By The Department Of Health And Human Services Screening assays for compounds that cause apoptosis and related compounds
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US6960570B2 (en) * 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7049063B2 (en) * 1998-03-18 2006-05-23 Corixa Corporation Methods for diagnosis of lung cancer
WO2001055454A1 (en) * 2000-01-28 2001-08-02 Althea Technologies, Inc. Methods for analysis of gene expression
DE60239535D1 (de) * 2001-06-18 2011-05-05 Rosetta Inpharmatics Llc Diagnose und prognose von brustkrebspatientinnen
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US20040009489A1 (en) * 2001-09-28 2004-01-15 Golub Todd R. Classification of lung carcinomas using gene expression analysis
WO2003087766A2 (en) 2002-04-05 2003-10-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma and of identifying therapeutic targets
US20040063120A1 (en) * 2002-07-10 2004-04-01 The Regents Of The University Of Michigan Expression profile of lung cancer
WO2004041196A2 (en) 2002-11-04 2004-05-21 The United States Of America, Represented By The Secretary Of Health And Human Services, Nih Methods and compositions for the diagnosis of neuroendocrine lung cancer
US20030153013A1 (en) * 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
CA2503621A1 (en) * 2002-11-13 2004-05-27 Genentech, Inc. Methods and compositions for diagnosing dysplasia
AU2003900747A0 (en) 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20040229225A1 (en) * 2003-05-16 2004-11-18 Jose Remacle Determination of a general three-dimensional status of a cell by multiple gene expression analysis on micro-arrays
WO2005015236A2 (en) 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma
BRPI0518734A2 (pt) 2004-11-30 2008-12-02 Veridex Llc prognàstico de cÂncer de pulmço
EP1777523A1 (de) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) In-vitro-Verfahren zur Prognose einer Tumorprogression und des Ergebnisses bei einem Patienten sowie Mittel zur Durchführung dieses Verfahrens
WO2007140352A2 (en) * 2006-05-26 2007-12-06 Invitrogen Corporation Plasma membrane and secreted cancer biomarkers

Also Published As

Publication number Publication date
WO2008009028A2 (en) 2008-01-17
WO2008009028A3 (en) 2008-04-10
EP2041313B1 (de) 2011-03-23
US9464324B2 (en) 2016-10-11
US20090258789A1 (en) 2009-10-15
EP2041313A2 (de) 2009-04-01
DE602007013405D1 (de) 2011-05-05

Similar Documents

Publication Publication Date Title
ATE446790T1 (de) Verfahren zur bestimmung der reichweite von strahlung
WO2006113747A3 (en) Diagnostic markers of breast cancer treatment and progression and methods of use thereof
DE60329377D1 (de) Methode zur vorhersage der sepsis in einem patienten mit systemischem inflammatorischem response-syndrom (sirs)
ATE536553T1 (de) Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse
ATE506448T1 (de) Verfahren zur l-aminosäureherstellung mittels fermentation
AR053272A1 (es) Determinacion de responsivos a la quimioterapia
NO20080371L (no) Fremgangsmate for a forutsi responsen overfor en behandling
WO2010083252A3 (en) Ratio based biomarkers and methods of use thereof
ATE503025T1 (de) Verfahren zur bestimmung der prognose eines adenokarzinoms
EP1860553A3 (de) Verfahren und Vorrichtung zur Virtualisierung von Fensterinformationen
HK1149956A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
MX2013003929A (es) Biomarcadores de citoquina como marcadores predictivos de respuesta clinica para acetato de glatiramer.
WO2009003706A3 (en) Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
WO2007023191A3 (de) Polypeptidmarker zur diagnose von blasenkrebs
DE69405232D1 (de) Verfahren zur bestimmung von salmonella
DE50313671D1 (de) Verfahren zur generierung eines gentechnisch veränderten organismus für das wirksubstanzscreening
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
ATE469917T2 (de) Verfahren zur gewinnung von antikörpern
NZ551782A (en) Agents and methods for diagnosing stress
Tang et al. Combined signature of nine immune-related genes: a novel risk score for predicting prognosis in hepatocellular carcinoma
ATE446384T1 (de) Verfahren zur amplifikation von nukleinsäuren mittels promotor-templates
RU2011142986A (ru) Способы лечения и диагностики рака
ATE408712T1 (de) Verfahren zur bestimmung des wiederauftretens von prostata krebs
BRPI0311182A2 (pt) método para isolar uma célula endotelial e método para realizar provas cruzadas específicas para o doador
WO2007013670A3 (en) Gene galnt6 as breast cancer marker and small interfering rnas directed against gene galnt6

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties